Jeremy Larsen, MD
Mayo Clinic
Rochester, Minnesota, USA
Free light chain assay and cytogenetic abnormalities for identification of high-risk smoldering myeloma
Translocation (4;14) and deletion 17p in smoldering multiple myeloma (SMM) have been identified as high risk cytogenetic abnormalities (CAs). Risk stratification incorporating CAs and biomarkers are needed to identify high risk SMM patients. The aim of this study was to determine the predictive value of the free light chain (FLC) assay in combination with high-risk CAs.
Visit our website at: http://www.myeloma.org